Laryngeal Lymphomatoid Granulomatosis in a HIV Patient

Granulomatosis linfomatoide laringea en paciente VIH positivo

To the Editor:

Lymphomatoid granulomatosis (LG) is a rare entity which was first reported in 1972 by Liebow et al.1 It is defined as a lymphoproliferative disorder caused by an Epstein-Barr virus-induced transformation of B-cells in a T-cell rich environment.

LG can first appear with a huge variety of non-specific symptoms. Pulmonary lesions are found in almost all patients with LG. Extrapulmonary disease without lung involvement is uncommon and a laryngeal primary kind is exceptional.

The case of a 34-year-old man, heavy smoker of 30 cigarettes a day and suffering from HIV-1 infection is reported. Five years before his admission to our hospital, he was diagnosed with HIV-1 infection, probably sexually transmitted, in context of pulmonary tuberculosis and was subsequently treated with a nine-month chemotherapy course for tuberculosis and Tenofovir-Lamivudine-Efavirenz. The tuberculosis was successfully cured with this treatment. Later, the HAART was changed to Zidovudine-Lamivudine-Nevirapine with poor disease control (30 CD4 cell count/μl and 20 copies HIV-1/ml).

In the previous two years, he was treated with Abacavir-Lamivudine-Lopinavir/ritonavir with discordant response (last test before admission: 138 CD4 cell count/μl and 20 copies HIV-1/ml). Throughout his illness, he has suffered from two episodes of community acquired pneumonia.

The patient was admitted to our centre because of a fever syndrome of unknown origin which he had suffered for several months, as well as a recent dysphonia. The endoscopic examination of the larynx found bilateral Reinke’s edema. We did not find any cause to explain the fever.

Blood tests showed normochromic normocytic anemia and ESR 109 mm/h. CD4 count cell was 124 cells/μl and viral load 32 copies/ml. Chest radiograph was normal. No evidence of renal disease was found. Blood and urine cultures, mycobacterium and parasites tests, cytomegalovirus PCR assay and latex-cryptococcus antigen detection were negative. Tumor markers levels were not raised. A liver biopsy revealed unspecific hepatic granulomas which were cultured, but no mycobacteria grew in Löwenstein-Jensen medium. Bone marrow aspiration found non-specific alterations in all blood cells, related to an unknown illness.

A cervical CT discovered a thickening of both vocal cords, compatible with Reinke’s edema, but it extended into the subglottis and the normal sized laterocervical lymph nodes. Only laryngeal and cervical lymph nodes had values over their maximum standard in a PET/CT (SUV maximum 10.7).

The tissue biopsy was reported as polymorph lymphoid proliferation related to post-transplant lymphoproliferative disorder. Neither T-cell nor B-cell clonality was found in the histochimical study and flow cytometry. Flow cytometry characteristics were CD1a negative, CD-3 negative, CD-5 negative, CD-10 negative, CD-20 negative, CD-30 positive in large cells, CD-68 positive in macrophages and cells surrounding vascular structures, CD-79a negative, CD-99 negative and CD-117-c-Kit negative. The EBER “in situ” hybridization was positive, pointing out the presence of EBV. Ziehl-Neelsen, P.A.S. and Congo red stains were negative.

No treatment was given after the first biopsy and the subglottic mass grew fast and aggressively: over three months, it infiltrated the para-laryngeal space and destroyed cricoid cartilage. This local progress caused recurrent episodes of massive bleeding. We started him on steroids 1 mg/kg/day IV and cyclophosphamide 2 mg/kg/day IV treatment and an urgent total laryngectomy was performed due to the imminent risk of fatal haemorrhage. Two weeks after surgery, a large pharyngeal fistula was developed, showing necrotic tissues. Our patient died six months after being hospitalized, due to a severe local bleeding.

The histopathological examination of larynx showed an atypical lymphoid infiltration containing large lymphoid cells surrounding vascular structures accompanied by extensive areas of necrosis, and was finally reported as lymphomatoid granulomatosis grade III according to the proportion of EBV positive B cells.

The immunohistochemical analysis showed positivity for EBV-LMP-1 and negativity for CD20. The Ki67 labelling index was high. The PCR analysis showed polyclonal expansion of T-cells with the TCR and IgH gene, and positivity for of EBV with histosonda EBER (Fig. 1).

Figure 1. Atypical lymphoid infiltrate containing large lymphoid cells surrounding vascular structures, hematoxylin-eosyn, 10×. Positivity of EBV with histosonda EBER, immunoperoxidase stain, 40×.
A literature search with no date limits in PubMed using the keywords “lymphomatoid granulomatosis” and “larynx” found only two reported cases where LG affects the larynx, but in both of them, laryngeal disease was associated with pulmonary involvement.2,3 The larynx has its own lymphatic structure called larynx-associated lymphoid tissue (LALT). In the subglottis, LALT is replaced throughout life by a diffuse infiltration of strong intensity consisting predominantly of CD3-positive T lymphocytes with scattered CD20-positive B cells,4 therefore LG could be originated in subglottic tissues.

LG pathogenesis is unclear, but it has been linked to EBV and immunodeficiency. As regards the close to 100% EBV association with LG and the presumed wide expression of EBV latent encoded proteins, it has been strongly inferred that EBV is not just an immunodeficiency. As regards the close to 100% EBV association in subglottic tissues.

logically considered as diffuse large B-cell malignant lymphoma, 8 or immunodeficiency.

treated as a casual finding in patients with fever of unknown origin (STARHS) was developed in 19982 and used with the Abbott HIVAB

The serological testing algorithm for recent HIV seroconversion enviroment.5

polymorphic through monomorphic lymphoid proliferations.9

associated with immunodeficiency and are driven by EBV. Histo-

feration related to a post-transplant lymphoproliferative disorder but the first biopsy was reported as polymorph lymphoid prol-

Our current case was classified as grade III of LG, which is histo-

logically considered as diffuse large B-cell malignant lymphoma,8

but the first biopsy was reported as polymorphic lymphoid prolif-

eration related to a post-transplant lymphoproliferative disorder (PTLD), which can simulate a lower grade of LG. LG and PTLD are associated with immunodeficiency and are driven by EBV. Histopathologically, they present a morphological spectrum spanning polymorphic through monomorphic lymphoid proliferations.9

The distinctness of LG and PTLD has been emphasized by the difference in the immune response. While LG has a large population of background T-cells, PTLD is recognized by a poor T-cell enviroment.5

A better awareness of LG in recent years is at present allowing new therapeutic tools for this disease to be developed. Rituximab, a new monoclonal antibody anti-CD20 has shown promising results in some cases of LG with pulmonary involvement.10

Bibliografía


Emilio Domínguez-Durána∗, Rafael Luque-Márquezb, María Fontillón-Alberdíc, Antonio Abrante-Jiménez a

a Departamento de Otorrinolaringología, Hospital Universitario Virgen del Rocío, Sevilla, España
b Unidad de Enfermedades Infecciosas, Hospital Universitario Virgen del Rocío, Sevilla, España
c Departamento de Anatomía Patológica, Hospital Universitario Virgen del Rocío, Sevilla, España

∗ Autor para correspondencia.
E-mail address: emiliodominezorl@gmail.com
(E. Domínguez-Durán).

doi:10.1016/j.eimc.2011.02.017

Comparison of Two Serological Tests for the Identification of Recent HIV Infection: Vironostika HIV-1 Microelisa and BED Capture Enzyme Immunoassay

Comparación de dos tests serológicos para la identificación de infecciones recientes por VIH-1: microelisa Vironostika HIV-1 y enzimoinmunoensayo de captura BED

To the Editor:

Identification of recent human immunodeficiency virus (HIV) infection is an important tool for monitoring HIV transmission. During the last few years, several serological assays have been developed for this purpose and used in cross-sectional studies.1 The serological testing algorithm for recent HIV seroconversion (STARHS) was developed in 19982 and used with the Abbott HIVAB 3A11 assay (Abbott Laboratories, Abbott Park, Chicago, Illinois, USA) and with the Vironostika HIV-1 Microelisa System (bioMérieux SA, Marcy l’Etoile, France). The sensitivity of both assays was lowered in order to obtain a negative result in specimens with low antibody titers, such as those from individuals with a recent infection. These assays are no longer available, and laboratories have turned to new methods. The BED assay (Calypse Biomedical Corporation, Portland, Oregon, USA) measures anti-HIV IgG titers3 and includes a calibrator to ensure comparability of results. Furthermore, the BED assay is included in an external quality program offered by the Centers for Disease Control and Prevention (CDC, Atlanta, Georgia, USA).

In Catalonia, the STARHS was introduced using the Vironostika assay as part of the enhanced HIV/STI surveillance program in 2003. As the Vironostika assay has no longer been available since 2007, our laboratory changed to the BED assay in 2008. Our aim was to assess whether the results obtained by both techniques were comparable.